|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100050751 |
|
最近更新日期: Date of Last Refreshed on: |
2022-03-25 20:46:02 |
|
注册时间: Date of Registration: |
2021-09-04 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
请与我们联系上传伦理审批文件。 基于血清GP73水平测定的TIPS术后肝功能变化的研究 |
|
Public title: |
To investigate the hepatic function after TIPS based on GP73 level |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于血清GP73水平测定的TIPS术后肝功能变化的研究 |
|
Scientific title: |
To investigate the hepatic function after TIPS based on GP73 level |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
鲍应军 |
研究负责人: |
任伟新 |
|
Applicant: |
Bao Yingjun |
Study leader: |
Ren Weixin |
|
申请注册联系人电话: Applicant telephone: |
+86 15981743252 |
研究负责人电话: Study leader's telephone: |
+86 13909911031 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
baodazi@126.com |
研究负责人电子邮件: Study leader's E-mail: |
rwx1031@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
新疆乌鲁木齐市鲤鱼山南路137号 |
研究负责人通讯地址: |
新疆乌鲁木齐市鲤鱼山南路137号 |
|
Applicant address: |
137 Liushan Road South, Urumqi, Xinjiang |
Study leader's address: |
137 Liushan Road South, Urumqi, Xinjiang |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
新疆医科大学第一附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Xinjiang Medical University |
||
|
研究负责人所在单位: |
新疆医科大学第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Xinjiang Medical University |
||
|
是否获伦理委员会批准: |
否/No |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 |
||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
新疆医科大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Xinjiang Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
新疆乌鲁木齐市鲤鱼山南路137号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
137 Liushan Road South, Urumqi, Xinjiang |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-raised |
||||||||||||||||||||||
|
Target disease: |
Hepatocirrhosis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
测定TIPS手术前后血清GP73水平的变化,对比血清GP73水平与肝脏功能及肝性脑病发病率之间的关系,研究TIPS术对肝脏功能的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
The GP73 level of serum were measured before and after TIPS, the relationship between serum GP73 level and liver function and the incidence of hepatic encephalopathy was compared to study the influence by TIPS on liver function. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.获得已签名的知情同意书; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Obtain signed informed consent; |
||||||||||||||||||||||
|
排除标准: |
1.合并肝脏恶性肿瘤的患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with liver cancer; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-10-01 00:00:00至 To 2022-10-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2021-10-01 00:00:00 至 To 2022-10-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据于研究结束6个月以内采用临床试验公共管理平台向公众开放查询, http://www.medresman.org |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The raw data will open to the public with public management platform in the 6 months after the study complete, http://www.medresman.org |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |